



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

M/s. BSE Limited
Dalal Street, Fort
Mumbai 400 001
Script Code: 524816

1st July, 2024

Sub: Clarification /Confirmation on news item appearing in “ the HINDU BUSINESS LINE”

Dear Sirs,

To clarify, we have not spoken to the reporter covering the stated article on the Hindu Business Line captioned “**Natco Pharma mulling acquisition in RoW market to strengthen base business**” dated June 28, 2024. Our analysis of this news article points out that all aspects of this news article came from already publicly disclosed materials available with stock exchange filings made by NATCO Pharma Limited from time to time.

Further, we wish to state that the headline “**Natco Pharma mulling acquisition in RoW market to strengthen base business**” is a public knowledge and has been conveyed to the shareholders and stock exchanges at large through Investor Concalls submissions on November 21, 2023 and June 4, 2024. The same has been stated in our Investor Presentation submitted to stock exchanges dated May 29, 2024.

NATCO Pharma has also committed to invest US\$ 2 million or ₹ 15.01 crores in Cellogen Therapeutics Private Limited (“Cellogen”) across three tranches for a fully diluted stake of 5.38% and definitive agreements have been signed to that effect. Out of which, first tranche of ₹ 7.51 crores has already been invested in Cellogen Therapeutics. Cellogen is a research company involved in cell and gene therapies. Its advanced programme is related to development of CAR-T therapy. The same has been communicated through LODR submissions on January 17, 2024.

The news portion about the buyback and the position of NATCO on the matter of buyback has also been already communicated to shareholders and stock exchanges through Investor Concall submission on June 4, 2024.

The news portion about the business discussion on crop health business has also been already communicated to shareholders and stock exchanges through Investor Concall submission on June 4, 2024.

We would like to further inform you that our Company has communicated consistently and timely communicated to the Exchanges all events, information, and updates that could impact the operation and performance of the Company. This includes all price-sensitive information as required under Regulation 30 and other applicable regulations of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time.

The Company has not withheld any material information or events which, in our opinion, would impact the movement in the price of our securities. In case of any information or event that requires disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we will make the necessary disclosures in accordance with regulatory requirements.

Thanking you

Yours faithfully

For NATCO Pharma Limited

Venkat Ramesh Ch
Company Secretary &
Compliance Officer